NAICONS SRL

Their core work

NAICONS is an Italian biotech SME specialized in discovering and engineering natural products from actinomycete bacteria — microorganisms that are one of nature's richest sources of antibiotics and bioactive compounds. They bring deep microbiology and genome mining capabilities to EU consortia focused on antimicrobial resistance, industrial bioprocesses, and marine biodiversity. Their core work involves strain engineering, natural product discovery, and applying systems biology to unlock new pharmaceutical ingredients and disease-suppressive agents from microbial sources.

What they specialise in

How they've shifted over time

In their early H2020 period (2015-2019), NAICONS focused on fundamental microbial engineering — systems biology, lipid raft manipulation, actinomycete chassis design, and pharmaceutical compound production via NRPS and Type II PKS pathways. From 2021 onward, their work shifted decisively toward applied antimicrobial strategies and interdisciplinary approaches, incorporating graphene-based sensors, machine learning, microbiome analysis, and marine bioprospecting. This evolution shows a company moving from upstream microbial platform development toward downstream applications in infection control and sustainable agriculture.

NAICONS is moving toward applied antimicrobial solutions drawing on marine biodiversity and data-driven approaches (AI, big data), making them increasingly relevant for One Health and sustainable agriculture consortia.

How they like to work

NAICONS operates exclusively as a specialist partner — they have never coordinated an H2020 project, instead contributing deep microbiology expertise to larger consortia. With 82 unique partners across 19 countries, they maintain a broad European network rather than a tight cluster of repeat collaborators. This pattern suggests they are a valued niche contributor that consortium coordinators seek out for specific microbial discovery and engineering capabilities.

NAICONS has built an extensive network of 82 unique partners across 19 countries, reflecting broad European reach for a small biotech SME. Their participation in multiple MSCA training networks (Train2Target, CARTNET) likely connects them to a wide academic pipeline across Europe.

What sets them apart

NAICONS occupies a rare niche as a private SME with deep expertise in actinomycete biology and natural product discovery — a capability more commonly found in university labs. Their combination of strain engineering know-how, genome mining, and industrial bioprocess experience makes them a bridge between academic microbiology research and pharmaceutical/agricultural applications. For consortium builders, they offer a commercial partner that can move microbial discoveries toward product development, which strengthens exploitation plans in grant proposals.

Highlights from their portfolio

• TOPCAPI
  Largest single grant (EUR 535,000) — focused on optimizing actinomycete production for advanced pharmaceutical ingredients, directly aligned with their core commercial capability.
• MARBLES
  Most recent and longest project (2021-2026, EUR 434K) — signals their strategic pivot toward marine biodiversity and sustainable agriculture applications.
• PEST-BIN
  Unusual interdisciplinary combination of graphene sensors, machine learning, and infection microbiology — shows NAICONS expanding into data-driven and materials-based approaches.